CD274 and neoplasm: In PD-L1hi (≥50% tumor cells with membranous expression; anti-PD-L1 clone 22C3, Merck) patients (prevalence: 23.2%), ORR: 45.2%; median PFS: 6.3 months; median OS: not reached